About all

Side effects for zantac 150: Zantac (Ranitidine) Side Effects | NDMA Contamination


Zantac (Ranitidine) Side Effects | NDMA Contamination

Common side effects of Zantac (ranitidine) include headaches, diarrhea and nausea. These side effects are mild and temporary. Rare, serious Zantac side effects include liver failure, acute porphyria attacks in patients with acute porphyria and pneumonia.

What Are the Common Side Effects of Zantac (Ranitidine)?

Zantac made with ranitidine is no longer available on the U.S. market. The market withdrawal doesn’t affect Sanofi’s new Zantac 360 made with famotidine, and the information about side effects on this page is specifically for Zantac made with ranitidine.

The most common side effects of Zantac are mild and infrequent. They also don’t last very long. Because ranitidine is no longer available on the market, there is no new information on Zantac made with ranitidine and its side effects.

Zantac side effects may include:

  • Stomach pain

  • Constipation

  • Diarrhea

  • Headache

  • Drowsiness

  • Fatigue

  • Dizziness

  • Insomnia

  • Nausea

  • Vomiting

  • Rash

  • Dark urine

  • Shortness of breath

  • Chest pain

  • Jaundice

  • Fever

In clinical trials, the rate of Zantac side effects was very similar to those reported by people who took a placebo, or an inactive medicine, according to French researchers who published their work in Drug Safety.

Researchers in another study by Glaxo Wellcome looked at data from controlled clinical trials with more than 26,000 patients who took the drug for four weeks or more. They also looked at postmarketing surveillance studies and adverse event reports. Researchers “confirmed the excellent safety profile of ranitidine.”

But after the Valisure pharmacy alerted the FDA that batches of ranitidine contained high levels of N-nitrosodimethylamine, or NDMA, several manufacturers voluntarily recalled their ranitidine products.

On April 1, 2020, the FDA requested manufacturers immediately withdraw all prescription and over-the-counter ranitidine drugs from the market. While initial FDA testing found NDMA in ranitidine in low levels, new FDA testing confirmed that NDMA levels increase in ranitidine over time.

Headache is the most common ranitidine side effect reported in clinical trials.

Serious and Rare Zantac Side Effects

According to the drug’s insert, serious Zantac side effects are rare.  If you suffer any of the following side effects, talk to your health care provider.

Serious side effects of Zantac (ranitidine) include:

  • Clay-colored stools

  • Coughing up mucus

  • Dark urine

  • Easy bruising or bleeding

  • Irregular heartbeat

  • Loss of appetite

  • Severe blistering, peeling, and red skin rash with headache

  • Vision problems

  • Weakness

  • Yellowing of the eyes or skin

Central Nervous System

Rare cases of mental confusion, depression, agitation and hallucinations and reversible blurred vision have been reported. These mental issues have been reported most often in severely ill, elderly patients. Some people also reported vertigo, dizziness and involuntary motor disturbances.

Cardiovascular Side Effects

Cardiovascular issues with Zantac are extremely rare but have occurred. French researcher T. Vial and colleagues reported the risk was about 1 in 1 million patients.

These include abnormal heart rhythms that mostly occur during rapid intravenous treatment with ranitidine. They usually subside after stopping the drug. Other cardiac events include hypertension and premature ventricular beats.

Gastrointestinal Issues

Along with constipation, diarrhea and abdominal pain, researchers also received rare reports of pancreatitis.

Liver Failure and Hepatitis

People have reported rare instances of liver failure and hepatitis. Some of these people also suffered jaundice. If this happens, discontinue Zantac immediately and speak to a health care professional. According to the drug’s label, these conditions are usually reversible. In rare cases, people died because of liver injury.

Blood Disorders

Some people who took Zantac suffered blood count changes including low white blood cells and low platelets. Rare cases of low red blood cell counts, with or without bone marrow problems, and very rare cases of acquired immune hemolytic anemia have been reported.

Gynecomastia, Impotence and Decreased Sex Drive

According to the drug’s label, controlled studies in animals and humans didn’t show that Zantac caused impotence or abnormal enlargement of the breasts called gynecomastia. But men taking the drug have reported cases of impotence and decreased sex drive when taken at high doses for a long period of time. These were comparable to the general population.

Both males and females have reported rare instances of gynecomastia and galactorrhea, a milky nipple discharge.

How Often Do Serious Side Effects Occur?

Researcher J.G. Mills and colleagues reported on rare, serious side ranitidine effects and how often they occurred out of almost 24,000 people in clinical trials. Only about 1.65 percent of people suffered serious reactions.

Frequency (%) of Serious Side Effects in 23,672 People

  • Abdominal pain 0.13

  • Nausea and vomiting 0.08

  • Hemorrhage 0. 09

  • Chest pain 0.05

  • Pneumonia 0.05

  • Headache 0.06

  • Malaise/fatigue 0.04

  • Ischemic heart disease 0.06

  • Cardiac infarction 0.03

  • Lung neoplasm 0.01

  • Hypertension 0.04

  • Phlebitis (inflammation of a vein) 0.01

  • Backache 0.04

  • Mental disorder 0.08

  • Renal problems 0.07

  • Skin and soft tissue problems 0.08

  • Injury and poisoning 0.05

  • Infectious disease 0.02

  • Cerebrovascular disease 0.04

NDMA Contamination Side Effects

NDMA is a chemical that was once used in the production of rocket fuel, lubricants and other industrial products. It is also found in small amounts in food, soil, air and water and is a byproduct of water chlorination, according to the Environmental Protection Agency.

The chemical is known to cause cancer in animals and may cause cancer in humans. Some people who developed cancer filed lawsuits against Zantac drugmakers. The main cancer in Zantac lawsuits is bladder cancer, but other cancers such as stomach cancer, colon cancer, prostate cancer, kidney cancer, liver cancer and breast cancer have been linked to NDMA.

The EPA lists several symptoms of overexposure to NDMA.

Potential Side Effects of NDMA Toxicity

  • Abdominal cramps

  • Diarrhea

  • Enlarged liver

  • Fever

  • Headache

  • Jaundice

  • Nausea

  • Reduced function of liver, kidneys and lungs

  • Vomiting

The FDA has determined the safe dietary daily intake limit for NDMA consumption is 96 ng. In September 2019, the pharmacy Valisure told the FDA that it had tested brand name and generic Zantac and found NDMA levels as high as 3,267,968 ng per tablet.

According to Valisure, ranitidine contains molecules that may actually create NDMA when exposed to conditions that mimicked the human stomach.

In December 2019, the FDA announced it had not found that ranitidine forms NDMA in typical human stomach conditions. The agency told manufacturers to test all batches of ranitidine and instructed them not to sell batches that contain NDMA levels over 96 ng.

However, further FDA testing and evaluation confirmed that NDMA levels increase in ranitidine under normal storage conditions and especially when stored at higher temperatures, such as those during distribution and consumer handling. And the older the ranitidine product is, the greater the level of NDMA, the FDA found.

“These conditions may raise the level of NDMA in the ranitidine product above the acceptable daily intake limit,” the FDA said in an April 1, 2020, news release.

As a result, the FDA requested immediate market withdrawal of all ranitidine products, meaning neither new nor existing prescription or OTC ranitidine products will be available for use in the U. S.

Is Zantac Safe for Pregnant Women and Children?

In general, Zantac is safe for pregnant women and children. But researchers have not established safety and effectiveness in babies less than one month old in clinical trials, according to ranitidine’s medication label.

Zantac and Pregnancy

The FDA categorized Zantac as Pregnancy Category B. This means it is unlikely to affect an unborn baby. But mothers-to-be should talk to their health care providers about whether they should use it during pregnancy or breastfeeding.


In animal studies, researchers administered doses up to 160 times the human dose to rabbits and rats and found no evidence of harm to the fetus or fertility. But there have been no tests in pregnant women. The drug label recommends using the drug with caution and only if clearly needed.

Because ranitidine can travel through breast milk, nursing mothers should use caution.

Children and Babies

Zantac side effects in children one month to 16 years of age are similar to those found in adults, according to clinical trial data on the drug label.

Studies have previously shown that acid-reducing drugs such as Zantac are well tolerated by babies.

But emerging evidence suggests gastric acid inhibiting drugs may increase the risk of infections, bacterial overgrowth and other problems in children and babies, according to a study published by Mark Safe and colleagues in World Journal of Gastrointestinal Pharmacology and Therapeutics.

Before Taking Ranitidine

Ranitidine is generally safe, but not everyone should take it. People with preexisting conditions or who take certain medications should talk to their health care provider before taking the drug. Before taking ranitidine, tell your health care provider or pharmacist about any medical conditions you have or medications you take.

Warnings and Precautions

  • Tell your health care provider if you are allergic to ranitidine or any of the drugs in the same class called h3 blockers.

  • Tell your health care provider about all the medication, vitamins and supplements you take, especially if you take blood thinners such as warfarin. You may need to adjust your dose.

  • Tell your health care provider if you have ever had kidney or liver disease, phenylketonuria or porphyria. Zantac may trigger an acute porphyria attack.

  • Tell your health care provider if you have chest pain that isn’t like typical heartburn pain, especially if it is accompanied by nausea, sweating or dizziness. These symptoms could mean a heart problem.

Long Term Use & Withdrawal

In general, Zantac is safe for long-term use. But drugs that affect acid production like h3 blockers and proton pump inhibitors may affect how some vitamins like B12 are absorbed. A B12 deficiency can lead to anemia, dementia, neurological damage and other problems, some of which are irreversible.

A study by researcher Jameson R. Lam and colleagues found that people who took h3 blockers like Zantac for two or more years were more likely to have B12 deficiency than those who did not. The effect was greater in people who took proton pump inhibitors.

Zantac Withdrawal

People who used 300 mg of ranitidine for two months suffered indigestion that lasted about two days after stopping treatment.

Research has also tied long-term use of Zantac to withdrawal symptoms, mainly indigestion.

One study by British researcher A.D. Smith and colleagues found that people who used 300 mg of ranitidine for two months suffered indigestion after stopping treatment. The symptoms lasted for about two days on average and were the most severe on the second day after stopping the drug.

The Long-Term Side Effects of Zantac

The long-term side effects of Zantac are many. The most common side effects linked to Zantac and other ranitidine heartburn and reflux medications are temporary in nature and generally stop when you discontinue use. They may include:

  • Headache
  • Chest pain
  • Nausea
  • Shortness of breath
  • Vomiting
  • Diarrhea
  • Stomach pain

Rarely, serious side effects and adverse effects from the usage of Zantac have been reported, according to drug manufacturer Sanofi. Once the use of the medication is discontinued, the long-term effects of Zantac may improve. Some may require medical care or become long-term concerns. These include:

  • Liver function
  • Liver damages
  • Anemia
  • Heart problems
  • Vertigo
  • Meningitis and other brain-related complications
  • Dystonia

Long-Term Side Effects of Zantac and Other Ranitidine Products

According to the manufacturer of over-the-counter brand name Zantac pills, there have been a number of adverse reactions linked to long-term use of ranitidine, especially in higher doses of the prescription formula. A causal relationship has not been proven in every case, but these reported side effects occurred during clinical trials, post-marketing surveillance, and monitoring of patients taking these medications.

Some of the long-term side effects of Zantac include:

Blood System Disorders

Reversible cases of anemia, leukopenia, granulocytopenia, and thrombocytopenia, as well as more serious causes of agranulocytosis, pancytopenia, or neutropenia, have been reported. Marrow hypoplasia or marrow aplasia, aplastic anemia, and acquired immune hemolytic anemia may be possible and affect the person long-term.

Cardiac Disorders

Arrhythmias may occur, including tachycardia, sinus bradycardia, asystole, and extrasystole. Premature ventricular beats and atrioventricular blocks with sinus pauses are possible. Some people may also experience heart palpitations and an increase in blood pressure, which generally stops when the medication is discontinued.

Vision and Eye Disorders

Blurred vision and intraocular pressure changes may be possible, although this is generally reversible when the person stops taking the medication.

Gastrointestinal Disorders

Because Zantac reduces the acid in the stomach, it may have other effects on the digestive system, which could include constipation or diarrhea, nausea and vomiting, abdominal discomfort, and acute pancreatitis. Some people report rebound hypersecretion, meaning the body produces additional acid after the person discontinues this medication.

Liver Disorders

Reversible changes in liver function have been reported, as well as rare reports of hepatitis, jaundice, and cholestatic jaundice. Liver failure has been reported in conjunction with Zantac use, so any related side effects should prompt users to discontinue use immediately. Damage may be permanent in some cases.

Psychiatric Disorders

Elderly patients and those with renal impairment or those with kidney disease need to be especially careful with Zantac. Both groups report an increase in confusion, depression, agitation, and hallucinations.

Renal Disorders

The kidneys clear Zantac, so anyone with renal failure should be especially careful with this drug. Acute interstitial nephritis is possible, and nephrotoxicity has been reported.

Reproductive Disorders

Zantac has been linked to temporary impotence and libido loss, both of which are treatable side effects. Other reproductive side effects include gynecomastia and galactorrhea.

Zantac can be particularly useful in treating the symptoms of acid reflux and heartburn. However, many have also reported adverse side effects after taking ranitidine products. Thankfully, most of these are not serious and do not last once the drug is stopped.

Headache, malaise, dizziness, vertigo, and other side effects fade quickly without medical attention. Allergic reactions or anaphylactic reactions, however, are also possible.

Understanding the Lawsuits Against Zantac

Zantac is an acid-reducer drug widely used in the United States since the mid-1980s. It reduces stomach acid and helps relieve heartburn, indigestion, and other symptoms of acid reflux. Zantac is also prescribed for peptic ulcers and GERD, which can sometimes lead to Barrett’s esophagus. It has proved to be a very effective treatment for these conditions for many people over the years.

Possible links between Zantac and certain types of cancer have been raised by health authorities worldwide. Although there is still no consensus on whether there is indeed a link between the two, Zantac litigation marches on in the form of individual product liability claims.

In September 2019, it was discovered that some brand name and generic versions of the pill might contain a possible carcinogen called NDMA, prompting widespread Zantac recalls. Multidistrict Litigation (MDL) No. 2875 concerns this carcinogen as well.

Paperwork that’s part of the multidistrict litigation alleges that ranitidine can cause tumors at many sites throughout the body, leading to several types of cancers, including:

  • Bladder cancer
  • Esophageal cancer
  • Intestinal cancer
  • Kidney cancer
  • Liver cancer
  • Pancreatic cancer
  • Stomach cancer
  • Colorectal cancer

There are thousands of lawsuits filed based on the dangers of the long-term side effects of ranitidine drugs. Makers of a generic version of Zantac have already settled one claim for $500,000. Though recent developments have brought multidistrict litigation to a halt, many individual personal injury and product liability lawsuits are going forward.

Manufacturers Were Aware of Carcinogens in the Medication

The FDA approved the prescription and over-the-counter versions of Zantac and generic ranitidine in 1983, and since then, millions of consumers have been using it to treat and prevent heartburn, GERD, and stomach ulcers. No warnings were given about the potential cancer risks that came with this medication.

The manufacturers of Zantac as well as the FDA, were aware of possible long-term side effects of ranitidine but didn’t make any mention of there being a risk regarding cancer. It was discovered recently that ranitidine is inherently unstable and can be converted into NDMA, a probable carcinogen, once entering your body.

This dangerous conversion was not made known to consumers or those taking ranitidine for their heartburn relief before now. This means that many people unknowingly put themselves at risk for possibly developing cancers without their knowledge or consent.

Talk to a Zantac Cancer Lawyer About Your Case

If you used Zantac or another ranitidine product to treat heartburn or gastroesophageal reflux disease (GERD) and later received a cancer diagnosis, you may want to discuss your case with a member of Zanes Law.

We can review your case for free and explain your options for pursuing compensation through legal action. Contact us today to get started with your free consultation.

Zantac. Effervescent tablets Reference book of medicines. Kyzyl (Republic of Tyva)

//= $single_post[“name_eng”] ?>
//= $single_post[“name_eng”] ?>


Effervescent tablets

Pharmacological action

Reduces basal and stimulated secretion of hydrochloric acid caused by baroreceptor irritation, food load, the action of hormones and biogenic stimulants (gastrin, histamine, pentagastrin). Reduces the volume of gastric juice and the content of hydrochloric acid in it, increases the pH of the contents of the stomach, which leads to a decrease in the activity of pepsin. Duration of action after a single dose 12 hours

Indications for use

Treatment and prevention:

– exacerbations of peptic ulcer of the stomach and duodenum;

– ulcers of the stomach and duodenum associated with the use of NSAIDs;

– reflux esophagitis, erosive esophagitis;

– Zollinger-Ellison syndrome;

– treatment and prevention of postoperative, “stress” stomach ulcers;

– prevention of recurrence of bleeding from the upper gastrointestinal tract;

– prevention of aspiration of gastric juice during operations under general anesthesia (Mendelssohn’s syndrome).

Presentation form

Effervescent tablets 150 mg; tuba 10 box (box) 1;

Tablets for the preparation of an effervescent drink 300 mg; polypropylene tube 15 carton pack 1;

Tablets for the preparation of an effervescent drink 300 mg; tuba 10 box (box) 1;

Tablets for the preparation of an effervescent drink 150 mg; polypropylene tube 15 carton pack 1;


Reduces basal and stimulated secretion of hydrochloric acid caused by irritation of baroreceptors, food load, the action of hormones and biogenic stimulants (gastrin, histamine, pentagastrin). Reduces the volume of gastric juice and the content of hydrochloric acid in it, increases the pH of the contents of the stomach, which leads to a decrease in the activity of pepsin. Duration of action after a single dose 12 hours


Oral bioavailability is approximately 50%, Cmax in plasma is reached 2-3 hours after ingestion. Plasma protein binding does not exceed 15%. Partially metabolized in the liver. It is excreted mainly by the kidneys in unchanged form by tubular secretion, a small amount – with feces. The metabolism of ranitidine does not differ between parenteral and oral administration and proceeds with the formation of small amounts of N-oxide (6%), S-oxide (2%), desmethylranitidine (2%) and furoic acid analogue (1-2%). It has the effect of “first pass” through the liver. Poorly passes through the BBB, passes through the placenta, passes into breast milk (the concentration in breast milk of women during lactation is higher than in plasma).

Use during pregnancy

During pregnancy and lactation, it should be used only in cases where the potential benefit to the mother outweighs the possible risk to the fetus or child (ranitidine passes through the placenta, passes into breast milk).

Contraindications for use

Hypersensitivity to ranitidine or any other component of the formulation; pregnancy, lactation; children’s age (up to 12 years).

With caution: renal and / or liver failure, cirrhosis of the liver with a history of portosystemic encephalopathy, acute porphyria (including history).

Side effects

From the nervous system and sensory organs: headache, fatigue, dizziness, drowsiness, insomnia, vertigo, anxiety, depression; rarely – confusion, hallucinations (especially in elderly and debilitated patients), reversible blurred vision, impaired accommodation of the eye.

From the side of the cardiovascular system and blood (hematopoiesis, hemostasis): arrhythmia, tachycardia / bradycardia, AV blockade, lowering blood pressure; reversible leukopenia, thrombocytopenia, granulocytopenia; rarely – agranulocytosis, pancytopenia, sometimes with bone marrow hypoplasia, aplastic anemia; sometimes – immune hemolytic anemia.

From the digestive tract: nausea, vomiting, constipation / diarrhea, abdominal discomfort / pain; rarely – pancreatitis. Sometimes – hepatocellular, cholestatic or mixed hepatitis with / without jaundice (in such cases, taking ranitidine should be stopped immediately). These effects are usually reversible, but in rare cases, death is possible. Rare cases of liver failure have also been reported.

From the musculoskeletal system: rarely – arthralgia, myalgia.

Allergic reactions: skin rash, bronchospasm, fever, eosinophilia; rarely – erythema multiforme, anaphylactic shock, angioedema.

Others: rarely – alopecia, vasculitis; in some cases – gynecomastia, decreased potency and / or libido. With prolonged use, the development of B12-deficiency anemia is possible.

Method of administration and dosage

Effervescent tablets: dissolve in water before taking (not less than 75 ml for a 150 mg tablet and not less than 150 ml for a 300 mg tablet).

Patients with renal insufficiency with Cl creatinine

Peptic ulcer of the stomach and duodenum: for the treatment of exacerbations, 150 mg 2 times a day (morning and evening) or 300 mg 1 time per day (at night) are prescribed. If necessary – 300 mg 2 times a day. The duration of the course of treatment is 4–8 weeks. For the prevention of exacerbations, 150 mg is prescribed once a day (at night).

Ulcers associated with taking NSAIDs: appoint 150 mg 2 times a day (morning and evening) or 300 mg 1 time per day (at night) for 8-12 weeks. Prevention of the formation of ulcers when taking NSAIDs – 150 mg 2 times a day (morning and evening).

Postoperative ulcers: 150 mg 2 times a day (morning and evening) for 4-8 weeks.

Gastroesophageal reflux disease: 150 mg 2 times a day (morning and evening) or 300 mg 1 time per day (at night). If necessary, the dose can be increased to 150 mg 4 times a day. The course of treatment is 8–12 weeks.

Zollinger-Ellison Syndrome: The initial dose is 150 mg 3 times a day. If necessary, the dose may be increased.

Prevention of recurrent bleeding: 150 mg 2 times a day (morning and evening).

Prevention of the development of Mendelssohn’s syndrome: prescribed at a dose of 150 mg 2 hours before anesthesia, and preferably 150 mg the evening before.


Symptoms: convulsions, bradycardia, ventricular arrhythmias.

Treatment: symptomatic and supportive therapy. With the development of seizures – diazepam IV, with bradycardia or ventricular arrhythmias – atropine, lidocaine. effective hemodialysis.

Interaction with other drugs

When used in recommended doses, ranitidine does not suppress the cytochrome P450-oxygenase system of the liver and does not enhance the activity of drugs that are inactivated by this system, incl. diazepam, lidocaine, phenytoin, propranolol, theophylline and warfarin.

Smoking reduces the effectiveness of ranitidine.

Ranitidine increases the AUC and the concentration of metoprolol in the blood serum (by 80 and 50%, respectively), while the T1 / 2 of metoprolol increases from 4.4 to 6.5 hours.

Due to the increase in the pH of the contents of the stomach, while taking itraconazole and ketoconazole, the absorption may decrease.

It inhibits the metabolism in the liver of phenazone, aminophenazone, diazepam, hexobarbital, propranolol, lidocaine, phenytoin, theophylline, aminophylline, indirect anticoagulants, glipizide, buformin, metronidazole, calcium antagonists.

Drugs that depress the bone marrow increase the risk of neutropenia.

When used simultaneously with antacids, sucralfate in high doses, ranitidine absorption may be impaired, so the interval between taking these drugs should be at least 2 hours.


Treatment with ranitidine may mask symptoms associated with gastric carcinoma, so patients with gastric ulcer should be excluded from the possibility of malignancy prior to treatment.

Ranitidine is excreted through the kidneys, so the plasma concentration of the drug increases in severe renal failure (in this case, the dose should be adjusted).

During treatment, you should avoid eating foods, drinks and other drugs that can cause irritation of the gastric mucosa.

Storage conditions

List B.: At a temperature not exceeding 30 °C (do not freeze).

Shelf life

24 months

Zantak in Vladivostok – instructions for use, description, reviews of patients and doctors, analogues

Products from the category – Stomach, intestines, liver

See all products from the category – Stomach, intestines, liver

Few facts about this product:

Instructions for use

    Presentation, composition and packaging

    Zantac belongs to the group of histamine H2 inhibitors. It is produced in liquid and tablet form. Dragees can be regular or effervescent. The main active ingredient is ranitidine at a dosage of 0.15, 0.3 g. Biconvex products are covered with a white film. One side is marked GX EC2. Auxiliary ingredients include: magnesium salt of stearic acid, cellulose microsorbent, titanium dioxide, hydroxypropyl cellulose, glycerol triacetate. The product is packaged in blisters of 10 pcs.
    The liquid mixture for injection is colorless or has a light yellow tint. The dose of the active element is 25, 50 mg. It is contained in glass ampoules in a volume of 2 ml. The price of Zantac is set depending on the form of the chemical product.

    Pharmacological action

    The antiulcer drug reduces the secretion of hydrochloric acid caused by the stimulation of interoreceptors, food, the influence of biogenic amines, and gastric hormones. From the description of chemical reactions, it is known that the substance reduces not only the volume of the liquid product synthesized by the pituitary membrane of the stomach, but also the level of hydrogen chloride and the proteolytic enzyme of the hydrolase class in it. It also provides an increase in the pH of the contents of the gastrointestinal tract, reducing the level of enzyme stimulation. The total time of the active state of the material after the first intake is 12 hours.
    The presence of Helicobacter pylori is found in most patients with ulcerative-erosive formations of the gastrointestinal tract. With the complex administration of an inhibitor of histamine H2 receptors with metronidazole or amoxicillin at 9In 0% of episodes, the suppression of a spiral gram-negative microbe is recorded. As a result of such treatment, the number of relapses of pathologies of the digestive system is reduced.
    After oral administration, the bioavailability of the drug reaches 50%. Maximum saturation occurs after 2-3 hours, and after intramuscular injection – after 15 minutes. The degree of interaction with plasma proteins is not higher than 15%. The active material enters the placenta and is found in breast lactose, where its density is higher than in blood plasma. Reactions for the splitting of the pharmaceutical product do not differ from the method of its introduction. The half-life is from 2 to 3 hours. Up to 70% of the initial amount of the drug is removed with urine, 26% through the intestines.


    Zantac is prescribed for the diagnosis of gastrointestinal ulcers of various origins, reflux, prolonged dyspepsia with concomitant epigastric and retrosternal pain. It is taken as a preventive measure against the development of pathologies as a result of stress or recurrent ulcerative conditions.


    The drug is not allowed for administration with pronounced porphyria, hypersensitivity to the components of the drug, as well as during the period of gestation, lactation and children under 12 years of age. Caution must be exercised when using the substance if renal or hepatic dysfunction, cirrhosis is detected.
    You can buy Zantac in a pharmacy or in an online prescription store.

    Dosage and Administration

    Adult patients with a worsening condition with a pathology of gastrointestinal ulcers are recommended to take two doses of tablets of 0.15 g or 0.3 g in the evening. Most ulcers heal within a month. If during this time the affected walls have not healed, then the portion is increased to 0.3 g 2 times a day. Doubling the dose does not cause complications.
    For long-term treatment in order to prevent the occurrence of recurrence of gastrointestinal ulcers, 0.15 g is prescribed once a day. If the patient smokes, then the norm is 0.3 g.
    Parenteral administration is used when the patient cannot take food. The solution is administered at a slow pace (at least 2 minutes) with an interval of 6-8 hours.

    Side effects

    Against the background of the use of the drug Zantak, the development of accidental phenomena from the side is possible:

    • indigestion – nausea, abdominal pain, dry mouth, pronounced inflammation of the pituitary surface of the pancreas, hepatitis with or without jaundice;
    • blood formation systems – a decrease in the number of leukocytes and platelets in the blood, anemia, oppression of the hematopoietic function;
    • heart and blood vessels – lowering blood pressure, rising or falling pulse rate;
    • central nervous organization – cephalgia, dizziness, asthenia, sleep disorders, accommodation, motor motor skills, depressed psychological state, hallucinations;
    • musculoskeletal system – pain in muscles and joints;
    • dermatology – hair loss;
    • immunity – skin rash, nettle fever, drop in blood pressure, anaphylactic shock, chest pain;
    • endocrinology – increased content of prolactin (pituitary hormone) in the blood substance.

    Delivery of Zantac in Moscow is carried out around the clock.


    As a result of the introduction of an overdose of the drug, signs of a reduced heart rate, ventricular arrhythmia appear, and convulsions develop. Therapy is to eliminate unwanted symptoms. The active component of the drug is removed using the extrarenal blood purification procedure.

    Drug interactions

    The combination of Zantac with pharmaceutical products intended for the treatment of acid-dependent diseases of the gastrointestinal tract, as well as with sucralfate in large quantities, causes damage to the mechanism of absorption of the active ingredient. The interval between the use of such substances should be at least two hours.
    With the parallel introduction of materials that suppress the functions of the bone marrow, the likelihood of neutropenia increases. The blocker of histamine H2 receptors does not reduce the activity of cytochrome P450 enzymes. Therefore, an increase in the action of muscle relaxants, anticonvulsants, antiepileptics, hypnotics, non-selective adrenoblockers, anticoagulants is not observed.
    According to the instructions, ranitidine inhibits the breakdown of antipyretics, analgesics, non-inhalation anesthesia, hypoglycemic substances. Due to the growth of the hydrogen index of the stomach with complex administration, a decrease in the absorption of antifungal chemicals is observed.
    Against the background of the introduction of antiulcer material, an increase in the total concentration of bitartrate in the serum mass of the blood medium is recorded with a simultaneous increase in the half-life of the latter from 4.5 to 6.5 hours.
    Zantak’s analogues are Atsilok, Zantin, Ranitin.

    Special instructions

    Therapy with the introduction of the drug can hide the signs of stomach cancer. In this regard, in patients with ulcerative-erosive phenomena, an appropriate diagnosis should be carried out before the appointment of antiulcer substances. Long-term treatment of patients, aggravated by stressful conditions, causes damage to the digestive tract by infectious pathogens.
    Effervescent tablets contain sodium. With its increased content, precautions must be taken. People with impaired amino acid metabolism should be careful when taking the effervescent chemical because it contains aspartame. With the rapid introduction of the solution in people with a reduced heart rate, the phenomenon of cardiac arrhythmia was recorded. When treating elderly people taking ranitidine with non-steroidal anti-inflammatory chemicals, constant monitoring of their health is necessary. There is information about the development of pronounced paroxysms of porphyria. For this reason, Zantak, according to doctors, is not prescribed.
    During the course of therapy, food and drinks that can irritate the pituitary surface of the gastrointestinal tract are not allowed. Tobacco smoking reduces the effectiveness of the use of antiulcer chemicals. As a result of parenteral infusion in large doses, activation of liver enzymes is recorded.